פרדקסה 75 ישראל - עברית - Ministry of Health

פרדקסה 75

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate

פרדקסה 75 ישראל - עברית - Ministry of Health

פרדקסה 75

boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - קפסולות - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate

דביגאטרן טבע  150 מג ישראל - עברית - Ministry of Health

דביגאטרן טבע 150 מג

teva israel ltd - dabigatran etexilate as mesylate - קפסולות - dabigatran etexilate as mesylate 150 mg - dabigatran etexilate

דביגאטרן טבע  110 מג ישראל - עברית - Ministry of Health

דביגאטרן טבע 110 מג

teva israel ltd - dabigatran etexilate as mesylate - קפסולות - dabigatran etexilate as mesylate 110 mg - dabigatran etexilate

דביגאטרן טבע  75 מג ישראל - עברית - Ministry of Health

דביגאטרן טבע 75 מג

teva israel ltd - dabigatran etexilate as mesylate - קפסולות - dabigatran etexilate as mesylate 75 mg - dabigatran etexilate

היקומיצין ישראל - עברית - Ministry of Health

היקומיצין

teva israel ltd - hydrocortisone; neomycin as sulfate - משחה - neomycin as sulfate 0.5 %; hydrocortisone 2.5 % - hydrocortisone and antibiotics - hydrocortisone and antibiotics - allergic dermatoses and other corticosteroid responsive inflammatory skin diseases including atopic dermatitis, contact dermatitis, seborrheic dermatitis, anogenital pruritus, infantile eczema and external otitis.

פרוטופיק % 0.03 ישראל - עברית - Ministry of Health

פרוטופיק % 0.03

dexcel ltd, israel - tacrolimus - משחה - tacrolimus 0.03 %w/w - tacrolimus - tacrolimus - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

פרוטופיק % 0.1 ישראל - עברית - Ministry of Health

פרוטופיק % 0.1

dexcel ltd, israel - tacrolimus - משחה - tacrolimus 0.1 %w/w - tacrolimus - tacrolimus - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

סנדאימון   ניאורל   50 מג כמוסות ישראל - עברית - Ministry of Health

סנדאימון ניאורל 50 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

סנדאימון   ניאורל   100 מג כמוסות ישראל - עברית - Ministry of Health

סנדאימון ניאורל 100 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.